BioSpace News Archive

Krystal Biotech, Inc. announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3rd Annual Genomic Medicines and Rare Disease Day.

Apellis Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 7,446,809 shares of its common stock at a public offering price of $47.00 per share, for total gross proceeds of $350 million, before deducting underwriting discounts and commissions and expenses payable by Apellis.

[24-March-2022] First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China , Hong Kong , Macau , Taiwan , Singapore , and South Korea Final cohort’s

Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29.

Today, AnaBios announced it will start providing high-quality human primary liver cells to pharmaceutical, biotech and academic laboratories to further improve the success of preclinical drug discovery research.

QIAGEN N.V. marked World TB Day by announcing its QuantiFERON blood test has been used to screen patients for tuberculosis infection more than 100 million times since its launch – an achievement that cements its status as the gold standard in the fight against this contagious and often deadly disease.

Glycotope GmbH, a biotechnology company developing antibodies against proteins carrying tumor-specific carbohydrate structures, announces that is has completed a re-focusing of its strategy to better deliver value from its powerful, proprietary glycobiology-informed technology platform.

MoonLake Immunotherapeutics AG, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced that it is proceeding with a global Phase 2 clinical study to evaluate sonelokimab in patients with moderate-to-severe hidradenitis suppurativa.

Spexis AG, a clinical-stage biopharmaceutical company, focused on rare diseases and oncology with an initial focus on chronic respiratory diseases, announced its financial results for the full-year of 2021 and provided a strategic business update.

Persica Pharmaceuticals Ltd announces that Peter Hamlyn, founding member and Non-Executive Director of Persica will be presenting at the 2022 British Association of Spine Surgeons meeting, taking place in Belfast on 23-25 March 2022.